

**HETEROGENEITY IN EFFICACY AND SAFETY ENDPOINTS FOR PEDIATRIC CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE: A NEED FOR HARMONIZATION**

E. Crowley<sup>5</sup>, D. Turner<sup>3</sup>, C. Ma<sup>2</sup>, T. Nguyen<sup>1</sup>, H. McKay<sup>4</sup>, R. Schneider<sup>4</sup>, A. Silverberg<sup>5</sup>, A. Muise<sup>4</sup>, B. Feagan<sup>5</sup>, A. Griffiths<sup>4</sup>, V. Jairath<sup>5</sup>

1. Alimentiv Inc, London, ON, Canada; 2. University of Calgary, Calgary, AB, Canada; 3. Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel; 4. The Hospital for Sick Children, Toronto, ON, Canada; 5. Western University, London, ON, Canada

NOT PUBLISHED AT AUTHOR'S REQUEST

**Funding Agencies:** None